


PERSONAL INFORMATION

Andrea Aiello



 via Licurgo 1, 20126, Milano, Italy

 +39 320 33 51 596

 andrea-aiello81@hotmail.it

Sex Male | Date of birth 06/12/1981 | Nationality Italian

WORK EXPERIENCE

 January 2019 -
Today

Project Manager

 Certara Italy – Milan, Italy. <https://www.certara.com/>

Strong analytical and commercial profile focusing on results and client satisfaction. Management of both National and International projects. Communicational and problem solving skills, developed through team-working also as team leader and self-managing on a number of economic and market access issues. Due to the specific background I have a solid understanding of market and different therapeutic areas, clients and payers' needs. Network of relations with Universities and public payers. Main activities:

- AIFA full Dossier;
- EMA and EUnetHTA Dossier;
- Budget Impact, Cost-Effectiveness, Cost-Utility and Cost-of-Illness analyses;
- Team working for the development of Pharmacoeconomic models;
- Interviews and Delphi panels;
- National and International Pricing and Reimbursement projects;
- International, National and Regional Decision Makers' Dossier submissions;
- Landscape analysis;
- Publications on International and National Journals;
- Global Value-Dossier development and adaptation to the Italian NHS;
- Data Base managing;
- Teamworking for the development of applications for tablets;
- Training courses in HTA, Market Access and Pharmacoeconomics;
- Professor for the lessons on Pharmacoeconomic and Budget Impact analysis at the Master of the University of Messina: "Farmacovigilanza, farmacoepidemiologia e farmacoconomia: valutazioni tramite utilizzo di real world data" 2018-2019

Business or sector Health and Pharmaceutical consulting

 September 2014 -
December 2018

Pricing & Market Access Manager

 Creativ Ceutical – Milan, Italy. www.creativ-ceutical.com

Strong analytical profile focusing on results. Management of both National and International projects. Communicational and problem solving skills, developed through team-working also as team leader and self-managing on a number of economic and market access issues. Network of relations with Universities and public payers. Main activities:

- AIFA full Dossier;
- Interviews and Delphi panels;
- Pharmacoeconomic Models adaptations and Budget Impact developmet;
- National and International Pricing and Reimbursement projects;
- International, National and Regional Decision Makers' Dossier submissions;
- Landscape analysis;
- Publications on International and National Journals;
- Global Value-Dossier adaptation to the Italian NHS;
- Data Base managing;
- Teamworking for the development of applications for tablets;
- Training courses in HTA, Market Access and Pharmacoeconomics;
- Professor for the lessons on Pharmacoeconomic and Budget Impact analysis at the Master of the University of Messina: "Farmacovigilanza, farmacoepidemiologia e farmacoconomia: valutazioni tramite utilizzo di real world data" 2016-2017 & 2017-2018

Business or sector Health and Pharmaceutical consulting

September 2011 –
August 2014

Health Economist

Centro Regionale Unico sul Farmaco (CRUF), Department of Pharmacy, Azienda Universitaria Integrata di Verona – piazzale Aristide Stefani, n.1, 37126 Verona, Italy.

Regional Policy Assessment, Public Decision-maker and Payer

Health Economist in Veneto Region with the responsibility of HTA drugs evaluations discussed by Regional Commission (CTRF Veneto) and specific sub-commissions (ROV – Oncologic Network Veneto). Involved in more than 150 evaluations and in several regional groups (i.e. Hepatitis C, HIV, oncology, atrial fibrillation, hematology etc.). Speaker in several national conferences and congress as spokesperson for Veneto Region. Involved as Strong analytical, communicational and problem solving skills developed through team-working and self managing on a number of HTA, statistic and economic issues. Main activities:

- HTA reports on drugs and medical devices (more than 150);
- Involved in several conferences and congresses as spokesman of Veneto Region;
- Involved in several HTA Regional groups and commissions;
- Budget Impact, Cost-Effectiveness, Cost-Utility and Cost-of-Illness analyses;
- Model adaptations;
- Regional Decision Makers' Dossier submissions;
- Data Base managing;
- Statistical evaluations and analysis;
- Training courses in HTA.

Business or sector Regional Policy Assessment, Public Decision-maker and Payer

October 2010 –
September 2011

Junior project manager

Pbe consulting srl - vicolo Stella, n.6, 37121 Verona, Italy.

- Budget Impact, Cost-Effectiveness, Cost-Utility and Cost-of-Illness analyses;
- Interviews and Delphi panels;
- Model adaptations;
- National and International Pricing and Reimbursement projects;
- National and Regional Decision Makers' Dossier submissions;
- Value-Dossier drafting;
- Observational studies on databases;
- HTA reports on drugs and medical devices;
- Statistical evaluations and analysis;
- Training courses in HTA and Pharmacoeconomics.

Business or sector Health and Pharmaceutical consulting

October 2009 –
September 2010

Health Economist

Unità di Valutazione ed Efficacia del Farmaco (UVEF), Department of Pharmacy, Azienda Universitaria Integrata di Verona – piazzale Aristide Stefani, n.1, 37126 Verona, Italy.

- Budget Impact, Cost-Effectiveness, Cost-Utility and Cost-of-Illness analyses;
- Model adaptations;
- Regional Decision Makers' Dossier submissions;
- HTA reports on drugs and medical devices;
- Data Base managing;
- Statistical evaluations and analysis;
- Training courses in HTA.

Business or sector Regional Policy Assessment, Public Decision-maker and Payer

February 2008 –
June 2009

Analyst

Centro di Epidemiologia e Biostatistica ed Informatica Medica (EBI), Università Politecnica delle Marche – via Tronto, n. 10/A, 60020, Ancona.

- Statistical and epidemiologic analysis;
- Data Base managing;
- Review of scientific studies.

Business or sector University

October 2006 –
April 2007

Internship

Pbe consulting srl - vicolo Stella, n.6, 37121 Verona, Italy.

- Budget Impact, Cost-Effectiveness, Cost-Utility and Cost-of-Illness analyses;
- Interviews and Delphi panels;
- Statistical evaluations and analysis.

Business or sector Health and Pharmaceutical consulting

December 2005 –
January 2008

Analyst

Department of Pharmacology, Università di Messina, Policlinico Universitario Messina “G.Martino” Pad. G , via Valeria, n.1, 98125, Messina, Italy.

- Drug safety;
- Data Base managing;
- Review of scientific studies;
- Statistical evaluations and analysis.

Business or sector University

EDUCATION AND TRAINING

September 2006 –
April 2007

No qualification awarded only certificates

Replace with EQF
(or other) level if
relevant

Department of Pharmacy, University of Padua, via L. Luzzatti, n.4 - 35131 Padova, Italy

Independent courses of:

- Pharmacoeconomics;
- Business Management, Marketing and Communication.

Degree in Economics, Statistical and Social Sciences

September 2000 –
July 2005

Università Commerciale Luigi Bocconi, via Sarfatti, n.25 - 20136 Milano, Italy.

- Microeconomics;
- Data Analysis;
- Economic Policies;
- Statistic.

PERSONAL SKILLS

Mother tongue(s) Italian

English	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
	Proficient	Proficient	Proficient	Independent	Independent

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Communication skills ▪ Good communication skills gained through my experience as a teacher at university and as a speaker at several courses.

Organisational / managerial skills ▪ Leadership (I had responsibility of 3 people working in the Veneto Region) and problem solving (I had responsibility of all the economic analysis for the Veneto Region)

Job-related skills ▪ Teamwork attitude and ability to work on own initiative (I worked also in multidisciplinary groups of 10 people).

Computer skills ▪ Good command of :
 ◦ Microsoft Office™ tools ;
 ◦ Stata™.

Other skills ▪ During my years at Bocconi University, from 2003 to 2005, I was elected as students representative for the degree course of Economics, Statistical and Social Sciences
 ▪ Swimming (agonistic activity)
 ▪ Played water polo (agonistic activity).

Driving licence ▪ Full (B)

ADDITIONAL INFORMATION

- Awards**
- SIFO (Italian Society of Hospital Pharmacist) 40th Annual Congress, 2019. SIFO 2 Posters selected as best Poster Research.
 - SIFO (Italian Society of Hospital Pharmacist) 40th Annual Congress, 2019. SIFO 2 Posters selected as Oral Presentation.
 - ISPOR (The Professional Society for Health Economics and Outcomes Research) 20th Annual European Congress, 2017. ISPOR Best Poster Research Presentation Finalist: Best General Poster Research Presentations.
 - ISPOR 19th Annual European Congress, 2016. ISPOR Best Poster Research Presentation Awards: Best General Poster Research Presentations.
 - Register as HTA Expert for AGENAS (Agenzia Nazionale per i Servizi Sanitari Regionali).

Publications
Presentations
Projects
Conferences
Seminars
Honours and awards
Memberships
References

Full Articles

- Scoglio R, Trifirò G, Sandullo A, Marangio G, D'Agate C, Costa S, Pellegrino S, Alibrandi A, Aiello A, Currò G, Cuzzupè C, Comisi F, Amato S, Conti Nibali R, Oteri S, Magazzù G, Carroccio A. Diagnostic Yield of Two Strategies for Adult Celiac Disease Identification in Primary Care. *J Clin Gastroenterol.* 2019 Jan;53(1):15-22. doi: 10.1097/MCG.0000000000000962.
- Aiello A, D'Ausilio A, Lo Muto R, Randon F, Laurenti L. Cost-Effectiveness Analysis of ibrutinib in Patients with Waldenström Macroglobulinemia in Italy. *J Mark Access Health Policy.* 2017; 5(1):1393308. doi: 10.1080/20016689.2017.1393308. ecollection 2017.
- D'Ausilio A, Aiello A, Esposito M., Graham C, Rocchia A, Giunta A, Altomare G. Cost-utility of secukinumab in Italian patients with moderate to severe plaque-type psoriasis. *Clinical Dermatology.* 2017; 5(2): 65-72.
- Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, Tagliaferri A; Potter Study Group. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. *Haemophilia.* 2017; 23(3):422-429.
- Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Damele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. *J Mark Access Health Policy.* 2017; 5(1):1283105. doi: 10.1080/20016689.2017.1283105. eCollection 2017.
- Ruggeri M, Aiello A, D'Ausilio A, Di Brino E, Cottone S, Ghezzi A, Lombardozi L, Mecozzi A, Sacchini D, Rocchia A, Mangone M, Toumi M. Evolution of the healthcare expenditure in Italy and effects of fingolimod increased prescribing in second line treatment of relapsing-remitting multiple sclerosis. *GRHTA* 2016; 3(3): 125–133.
- D'Ausilio A, Aiello A, Toumi M. Revisione della letteratura economica di deferasirox nel trattamento del sovraccarico cronico di ferro dovuto a frequenti emotrasfusioni in pazienti con beta talassemia major. *Giornale Italiano di Health Technology Assessment* 2015; 8(1):1-8.
- Pierelli L, Berto P, Accorsi P, Milone G, Lopatriello S, Aiello A, Iacopino P, Olivieri A, Rambaldi A, Bosi A. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. *Transphusion and Apheresis Science* 2013; 49(3) :615-22.
- Berto P, Aiello A, Giardino AM. Health Technology Assessment dell'Etanercept nel trattamento dell'artrite reumatoide. Capitolo 4: Aspetti biotecnologici di etanercept (ENBREL®). *Quaderni Italian Journal of Public Health* 2012; 3(1): 35-53.
- Berto P, Aiello A, Di Virgilio R. Health Technology Assessment dell'Etanercept nel trattamento dell'artrite reumatoide. Capitolo 5: Valutazioni economiche nell'artrite reumatoide. *Quaderni Italian Journal of Public Health* 2012; 3(1): 54-65.
- Berto P, Lopatriello S, Aiello A, Corcione F, Spinoglio G, Trapani V, Melotti G. Cost of laparoscopy and laparotomy in the surgical treatment of colorectal cancer. *Surgical Endoscopy* 2012; 26(5): 1444-53.
- Berto P, Aiello A. NICE e trattamenti di fine vita – PARTE 1. *Un Anno di Economia Sanitaria* 2010-2011. Pagine 84-86. Edizioni. SEED srl, Torino. 2011
- Berto P, Aiello A. NICE e trattamenti di fine vita – PARTE 2.. *Un Anno di Economia Sanitaria* 2010-2011. Pagine 87-90. Edizioni. SEED srl, Torino. 2011
- Aiello A La pubblicità diretta al consumatore per i farmaci da prescrizione, vantaggi e limiti.. published on: www.farmacovigilanza.org 2009
- Polimeni G, Russo A, Catania MA, Aiello A, Oteri A, Trifirò G, Calapai G, Sautebin L, Iacobelli M, Caputi AP Drug Safety Information Through the Internet: The Experience of an Italian Website" *Drug Safety* 2009; 32(3): 245-253.

Publications
 Presentations
 Projects
 Conferences
 Seminars
 Honours and awards
 Memberships
 References

Posters and Abstracts

- Aiello A, Berto P, Fedriga A. Un'analisi introduttiva degli sconti confidenziali per i farmaci oncologici e onco-ematologici nel triennio 2016-2018 in Italia. GIFAC 2019;33(3 Suppl. 1):e13.
- Aiello A, Berto P, Stanisic S, Colombo A, Teruzzi C. Un'analisi di Budget Impact - del Fattore IX ricombinante con tecnologia fc a emivita prolungata (rfixfc) - nel trattamento dell'emofilia b. GIFAC 2019;33(3 Suppl. 1):e13.
- Berto P, Aiello A, Ingrasciotta Y, Sultana J, Formica D, Ientile V, Chinellato A, Tari DU, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Genazzani A, Rossi M, Santoro D, Trifirò G. Direct healthcare costs of chronic kidney disease management in Italy: how much saving can be achieved with larger biosimilar uptake? Value in Health, Volume 22, S919 - S920.
- Aiello A, D'Ausilio A, Pizzimenti V, Formica D, Sultana J, Lucchesi S, Ientile V, Toumi M, Trifirò G. Budget impact of newly approved drugs by the Sicilian drug formulary committee: an introductory analysis. Value Health. 2017; 20(9):A669.
- Aiello A, D'Ausilio A, Pizzimenti V, Formica D, Sultana J, Lucchesi S, Ientile V, Toumi M, Trifirò G. An introductory analysis of the timeframe from European drugs approval to the Sicilian hospital formulary inclusion. Value Health. 2017; 20(9):A666.
- Belfiore P, D'Ausilio A, Aiello A, Toumi M, Scaletti A, Frau A, Ripani M, Romano Spica V, Liguori G. A cost consequences analysis of the human body posturizer in Italy. Value Health. 2017; 20(9):A582.
- Aiello A, D'Ausilio A, Kornfeld M, Toumi M. An introductory analysis on the economic burden of diabetes in Italy. Value in Health. 2017; 20(5): A1-A383.
- Polimeni G, Isgrò V, Aiello A, D'Ausilio A, D'Addetta G, Cuzzocrea S, Caputi AP, Toumi M. Role of clinical pharmacist in optimizing reimbursement originating from performance-based risk-sharing arrangements: the experience of the University Hospital "G. Martino" from Messina, Italy. Value Health. 2016; 19(7):A756.
- Aiello A, Guarino M, D'Ausilio A, Toumi M, Caporaso N, Morisco F. A real world cost analysis of serum HBsAg quantification test in patients with chronic hepatitis B: the case of the University of Naples Federico II. Value Health. 2016; 19(7):A690.
- Aiello A, D'Ausilio A, Latorre E, Toumi M. Alcoholism in Italy: an introductory analysis of consumption and hospitalisation trends. Value Health. 2016; 19(7):A629-30.
- Aiello A, D'Ausilio A, Randon F, Lo Muto R. Cost-Effectiveness analysis of ibrutinib for waldenström macroglobulinemia in Italy. Value Health. 2016; 19(7):A587.
- Cacciola I, Giardina C, Sirna V, Macri R, D'Ausilio A, Aiello A, Latorre E, Toumi M, Filomia R, Arcoraci V, Raimondo G, Caputi AP. Hepatitis C Treatment with First-Generation Protease Inhibitors in A Real-World Cohort: Risk-Benefit Profile and Costs of the Therapy. Value Health. 2016; 19(7):A511.
- Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Da Mele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S. Cost-Effectiveness of adding bedaquiline to background drug regimens for the treatment of multidrug-resistant and extensively-resistant tuberculosis in Italy. 2016; 9(7):A553-54.
- D'Ausilio A, Aiello A, Daniel F, Graham C, Rocchia A, Toumi M. A Cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Value Health. 2015; 18(7):A424.
- Daniel F, Aiello A, D'Ausilio A, Toumi M. Off-patent drugs consumption and expenditures in Italy:2009-2013. Value Health 2015; 18(7):A533.
- Tagliaferri A, Coppola A, Amoresano S, Aiello A, D'Ausilio A, Toumi M. Cost-utility analysis of antihemophilic Factor rFVII-fs for secondary prophylaxis vs on-demand therapy in severe haemophilia A in Italy. Value Health. 2015; 18(7):A671.
- D'Ausilio A, Daniel F, Aiello A, Toumi M. Italian healthcare expenditure trends from 2002 to 2013. Value Health. 2015; 18(7):A536.
- Aiello A, Daniel F, D'Ausilio A, Snedecor SJ, Toumi M. Cost-effectiveness of nilotinib in patients with chronic myeloid leukaemia eligible to start the treatment-free remission phase in Italy. Value Health. 2015; 18(7):A457.
- Adami S, Aiello A, Magrì MR, Nocera S, Piovesan S, Alberti A, Scroccaro G. Budget Impact Analysis of sofosbuvir for the treatment of Hepatitis C in the Veneto Region, Italy. Value Health. 2014; 17(7):A363-4.

Publications
 Presentations
 Projects
 Conferences
 Seminars
 Honours and awards
 Memberships
 References

Posters and Abstracts

- Aiello A, Adami S, Alberti C, Breda A, Facchin P, Magri MR, Michelon A, Rodeghiero F, Tommasi M, Visentin E, Scroccaro G. Analisi dei dati di consumo e di spesa dei concentrati di fattore VIII nella Regione Veneto. *Giornale Italiano di Farmacia Clinica* 2013; 27(3-4):252.
- Adami S, Aiello A, Palozzo AC, Magri MR, Visentin E, Chiarion V, Michelon A, Alberti C, Maran PR, Saugo M, Scroccaro G. Budget Impact Analysis of Ipilimumab for the Treatment of Advanced Melanoma in the Veneto Region, Italy. *Value Health*. 2013; 16 (7): A399.
- Magri MR, Adami S, Aiello A, Alberti C, Chiarion Sileni V, Maran PR, Michelon A, Palozzo AC, Saugo M, Visentin E, Scroccaro G. Progetto per la gestione in rete dei pazienti con melanoma metastatico sottoposti a trattamento con Ipilimumab nella Regione Veneto. *Giornale Italiano di Farmacia Clinica*. 2013; 27(3-4):416.
- Visentin E, Adami S, Aiello A, Alberti C, Doria A, Magri MR, Michelon A, Saugo M, Scroccaro G. Analisi di impatto sul budget di Belimumab nel trattamento del Lupus Eritematoso Sistemico (LES). *Giornale Italiano di Farmacia Clinica*. 2013; 27(3-4):415.
- Michelon A, Adami S, Aiello A, Alberti C, Biasi V, Magri MR, Maran PR, Visentin E, Scroccaro G, Venturini F. Impiego dei farmaci biologici in ambito reumatologico, dermatologico e gastroenterologico nell'Azienda Ospedaliera Universitaria Integrata di Verona: switch di terapia. *Giornale Italiano di Farmacia Clinica* 2013; 27(3-4):131.
- Biasi V, Adami S, Aiello A, Alberti C, Cattelan AM, Concia E, Fantelli V, Magri MR, Michelon A, Saugo M, Visentin E, Scroccaro G. L'utilizzo dei dati di spesa quale indicatore del profilo prescrittivo dei farmaci HIV. *Giornale Italiano di Farmacia Clinica* 2013; 27(3-4):251-2
- Maran PR, Aiello A, Magri MR, Alberti C, Visentin E, Venturini F, Scroccaro G. Cost Effectiveness Analysis in the Veneto Region of Nab-Paclitaxel Monotherapy II Line Versus Conventional Paclitaxel in Patients With Breast Cancer and for Whom Anthracyclines are Not Indicated. *Value Health*. 2012; 15(7): A423.
- Maran PR, Aiello A, Magri MR, Alberti C, Visentin E, Venturini F, Scroccaro G. Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen. *Value Health*. 2012; 15(7): A424.
- Adami S, Alberti C, Visentin E, Magri MR, Maran PR, Aiello A, Scroccaro G. Analisi degli studi registrativi di un campione di farmaci valutati dalla commissione tecnica regionale della Regione Veneto.. *Giornale italiano di Farmacia clinica* 2012; 26 (2-3):184-85.
- Aiello A, Bassotto F, Fraticello A, Ghirlanda G, Marini P, Fantelli V, Scroccaro G. The use of economic evaluation in a Medical Device Commission of an Italian Teaching Hospital. *Value Health* 2010; 13(7): A429.
- Alberti C, Berardo F, Aiello A, Venturini F, Scroccaro G. Full Hta Report Sulla Profilassi Del Tromboembolismo Venoso (Tev) In Chirurgia Sostitutiva Elettiva Di Anca E Ginocchio. *G. Giornale Italiano di Farmacia Clinica*. 2010; 24(3):306-307.
- Bassotto F, Aiello A, Filippi C, Fraticello A, Marini P, Fantelli V, Schirolli S, Ghirlanda G, Scroccaro G. Analisi Delle Prove Di Efficacia Clinica Ed Economica Dei Dispositivi Medici Valutati Presso L'azienda Ospedaliera Universitaria Integrata Di Verona. *Giornale Italiano di Farmacia Clinica*. 2010; 24(3):272-73.
- Alberti C, Venturini F, Berardo F, Visentin E, Aiello A, Maran PR, Scroccaro G. "New oral antithrombotic drugs for the VTE prevention in orthopaedic surgery: the HT assessment and appraisal process of the Veneto Region in Italy". 7th HTAi Congress. Dublin 6-9 September 2010.
- Polimeri G, Russo A, Catania MA, Trifirò G, Cupani C, Oteri A, Fava G, Alacqua M, Gentile M, Rossi A, Aiello A, Iacobelli M, Sautebin L, Calapai G, Caputi AP. Providing Reliable Pharmacovigilance Information via the Web: The Experience of an Italian Web Site. 7th Congress ISoP – Bournemouth, 21- 24 October 2007.
- Polimeri G, Russo A, Catania M, Trifirò G, Oteri A, Alacqua ML, Cupani C, Fava G, Gentile M, Sportiello L, Aiello A, Iacobelli M, Sautebin L, Calapai G, Caputi AP. Informazione indipendente sulla farmacovigilanza attraverso Internet: l'esperienza del sito web www.farmacovigilanza.org. *Giornale Italiano di Farmacia Clinica*. 2007; 21(3): 249-250.
- Ortolani C, Berto P, Frati F, Aiello A, Bertani G. "Effect of immunotherapy on drug use and cost in ragweed pollen allergic disease in Lombardia". *Value Health* 2007; 10(6): A402.

Publications

Presentations
Projects
Conferences
Seminars
Honours and awards
Memberships
References

Oral Presentations

- Visentin E, Alberti C, Maran PR, Aiello A, Magri MR, Miggiano C, Scroccaro G. Main concerns about bias submitted by stakeholders supporting the introduction of new drugs into the formulary of the Veneto Region. Presented at the 14th European Congress of the International Society of Pharmacoeconomics (ISPOR), Madrid 5-8 November 2011.
- Visentin E, Aiello A, Alberti C, Berardo F, Maran PR, Venturini F, Gasparetto T, Scroccaro G. The use of economic evaluations produced by UVEF for HTA report assessments in the Veneto Region. Presented at the 13th European Congress of the International Society of Pharmacoeconomics (ISPOR), Prague, 6-9 November 2010.

Publications
Presentations
Projects
Conferences
Seminars
Honours and awards
Memberships
References

Conferences and Courses where I was Speaker

- Lessons of Pharmacoeconomics and Budget Impact Analysis at the University Master of the Messina University: "Farmacovigilanza, farmacoepidemiologia e farmacoecologia: valutazioni tramite utilizzo di real world data". Messina years 2016 – 2017.
- Presentation: "BPCO: ma quanto mi costi?" Course Continuing medical education (CME): "Valutazione dell'efficacia di interventi di formazione rivolti alla Medicina Generale sul miglioramento dell'appropriatezza prescrittiva e gestionale dei pazienti affetti da broncopneumopatia cronica ostruttiva (BPCO)". Palermo 30 September 2017
- Presentation: "Come le Regioni affrontano la scarsità di risorse" Conference: "Epatiti Virali: screening e accesso alle cure. Un piano nazionale per sconfiggere la malattia". Rome 26 June 2013.
- Presentation: "Panel: le necessità delle Regioni" Third Workshop of Economics and Drugs in Hepatology, WEF-E 2013. Rome 7-8 February 2013.
- Presentation: "Impatto dei nuovi farmaci antitrombotici in ambito regionale: il punto di vista della Regione Veneto. Valutazione di Impatto di Spesa" Course Continuing medical education (CME): "Nuove strategie nella terapia antitrombotica". Mestre 24 October 2012.
- Presentation and exercise: "L'analisi Costo-Beneficio". at the Course organized by University of Ferrara, Faculty of Medicine and Surgery: "Vaccinazioni: Consolidare i risultati guardando a nuove frontiere". Ferrara 20-22 October 2010.
- Presentation and exercise: "Il percorso di valutazione dei farmaci per la profilassi del tromboembolismo venoso in pazienti sottoposti a chirurgia sostitutiva elettiva totale dell'anca o del ginocchio". at the Course organized by the Accademia Nazionale di Medicina: "Valutazione pre/post marketing delle innovazioni tecnologiche. Trasferibilità, impatto, sostenibilità economica". Genoa 18-19 June 2010.
- Presentation: "Esempi di valutazioni economiche applicate ai dispositivi medici". at the Course organized by the Accademia Nazionale di Medicina: "Valutazione pre/post marketing delle innovazioni tecnologiche. Trasferibilità, impatto, sostenibilità economica". Genoa 18-19 June 2010.
- Presentation: "Applicazione dell'analisi economica nella valutazione dei trattamenti at the Conference of the Italian Society of Pharmacology (SIF): "La sostenibilità delle cure nella Regione Veneto". Padua 28 May 2010.
- HTA Course of Veneto Region: "Corso itinerante per le Aree vaste e Nuclei per l'appropriatezza d'impiego Farmaci e Dispositivi Medici: la valutazione delle tecnologie - Health Technology Assessment (HTA) - nelle organizzazioni sanitarie. Regione Veneto" March – June 2010.
- Seminar for post-graduate and PhD students in Pharmacy, Faculty of Pharmacy, University of Messina: "La valutazione economica in Sanità". Messina 26 January 2007.
- Seminar for post-graduate and PhD students in Pharmacology, Faculty of Medicine and Surgery, University of Messina: "La pubblicità diretta al consumatore per i farmaci da prescrizione". Messina 29 March 2006.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Signature, 